SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

SOPHiA GENETICS, a prominent player in the field of AI-driven precision medicine, has successfully closed its underwritten public offering, generating total gross proceeds of $57.5 million. This transaction, announced on June 19, 2026, reflects strong investor interest, leading to an oversubscribed offering. The company sold 12,104,900 ordinary shares at a price of $4.75 per share, which included an additional 1,578,900 shares purchased by underwriters, fully exercising their option to acquire more shares.

Founded with the goal of transforming patient care through data-driven medicine, SOPHiA GENETICS has established itself as a leader in the healthcare technology sector. The company’s flagship product, the SOPHiA DDM™ platform, leverages artificial intelligence to analyze complex genomic and multimodal data, providing actionable insights for healthcare providers worldwide. This recent capital raise will likely enhance the company’s ability to expand its offerings and further invest in its innovative platform, positioning it for continued growth in a competitive market.

The oversubscription of the offering underscores the robust demand for shares in companies that are at the forefront of technological advancements in healthcare. Investors are increasingly drawn to firms that utilize AI to improve patient outcomes and streamline healthcare processes. The successful completion of this IPO not only strengthens SOPHiA GENETICS' financial standing but also signals confidence from the investment community in the future of AI in healthcare.

The healthcare technology sector is experiencing significant momentum, driven by advancements in artificial intelligence and data analytics. As more companies seek to harness these technologies, the landscape is becoming increasingly competitive. SOPHiA GENETICS' ability to attract substantial investment capital positions it well to capitalize on emerging opportunities and navigate the evolving market dynamics.

Looking ahead, the successful public offering of SOPHiA GENETICS may serve as a bellwether for other companies in the healthcare technology space considering similar routes to raise capital. As investor appetite for innovative healthcare solutions continues to grow, it is anticipated that more firms will follow suit, leveraging public offerings to fuel expansion and innovation in this rapidly evolving sector.